AzTrials
AzTrials

Breast CancerMOZARTNCT07426809

Margin Optimisation Using Z-axis Assessment With Real-time Tomosynthesis (MOZART Study).

A study testing Standard 2D Specimen Mammography and Mozart 3D Specimen Radiography System in people with Breast Cancer, run by Royal College of Surgeons, Ireland at 1 site in Ireland.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Breast-conserving surgery is commonly performed to remove early-stage breast cancer or ductal carcinoma in situ (DCIS). During surgery, the goal is to completely remove the tumour with a clear margin of normal tissue around it. Read more about this study

Who is it for?
Ages 18 years and older, women onlyHealthy volunteers can take part
Conditions the study is for
Breast Cancer
What is being tested?
Standard 2D Specimen Mammography and Mozart 3D Specimen Radiography System
Could I receive a placebo?
No, everyone receives an active treatment
How many people
314 participants
Where
1 siteIreland
Study dates
18 Dec 2025to 31 Dec 2028
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • Women only
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Female patients
  • Age ≥ 18 years
  • Diagnosis of primary invasive breast cancer or ductal carcinoma in situ (DCIS)
  • Planned breast-conserving surgery with curative intent
  • No clinical or radiological evidence of distant metastatic disease at time of recruitment
  • Able to provide written informed consent
  • Fluent in English (spoken and written)

Who cannot join

  • Evidence of metastatic (stage IV) breast cancer
  • Planned mastectomy instead of breast-conserving surgery
  • Prior ipsilateral breast cancer surgery for the current malignancy
  • Inability to provide informed consent
  • Participation in another interventional study that may affect surgical margin assessment

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Prof Arnold Hill, MB, BCh, BAO, MCh, FRCSI contact

018093000

adkhill@rcsi.com

Aisling Hegarty, PhD contact

Aislinghegarty@rcsi.ie

Ireland1 site, 1 recruiting
  • Beaumont RCSI Cancer Centre

    Beaumont, Dublin, D09V2N0

    Aisling Hegarty, PhD, 0035317977800, Aislinghegarty@rcsi.ie

    Recruiting

Other trials in Ireland

About this study

Breast-conserving surgery is commonly performed to remove early-stage breast cancer or ductal carcinoma in situ (DCIS). During surgery, the goal is to completely remove the tumour with a clear margin of normal tissue around it. If cancer cells are found at the edge of the removed tissue (a "positive margin"), patients may need a second operation (re-excision). Re-excision can delay further treatment, increase patient anxiety, and increase healthcare costs.

To help assess margins during surgery, surgeons use specimen imaging. Standard practice involves two-dimensional (2D) specimen mammography, usually performed in the radiology department. This requires temporary transfer of the specimen out of the operating theatre and provides limited depth information.

Read more

The MOZART study is evaluating whether three-dimensional (3D) digital breast tomosynthesis, performed in the operating theatre using the Mozart system, improves margin assessment compared to standard 2D specimen mammography.

Patients undergoing breast-conserving surgery at Beaumont Hospital who agree to participate will be randomly assigned (like flipping a coin) to one of two groups:

Standard 2D specimen mammography (current standard practice), or

3D digital breast tomosynthesis performed in theatre.

In both groups, the operating surgeon will review the images during surgery and decide whether additional tissue needs to be removed. The final margin status will be determined by routine laboratory analysis after surgery.

The main goal of this study is to compare the rate of positive margins between the two imaging methods. Other outcomes include the need for additional surgery, operating time, and overall workflow efficiency.

The results of this study may help determine whether intraoperative 3D imaging improves surgical outcomes and reduces the need for re-excision in patients undergoing breast-conserving surgery.

Read the detailed description

Below are ClinicalTrials.gov-ready versions of both sections. They follow plain-language guidance, avoid promotional tone, and avoid duplicating structured registry fields.

Brief Summary

(Plain-language, patient-facing; within 5,000 characters)

Breast-conserving surgery is commonly performed to remove early-stage breast cancer or ductal carcinoma in situ (DCIS). During surgery, the goal is to completely remove the tumour with a clear margin of normal tissue around it. If cancer cells are found at the edge of the removed tissue (a "positive margin"), patients may need a second operation (re-excision). Re-excision can delay further treatment, increase patient anxiety, and increase healthcare costs.

To help assess margins during surgery, surgeons use specimen imaging. Standard practice involves two-dimensional (2D) specimen mammography, usually performed in the radiology department. This requires temporary transfer of the specimen out of the operating theatre and provides limited depth information.

The MOZART study is evaluating whether three-dimensional (3D) digital breast tomosynthesis, performed in the operating theatre using the Mozart system, improves margin assessment compared to standard 2D specimen mammography.

Patients undergoing breast-conserving surgery at Beaumont Hospital who agree to participate will be randomly assigned (like flipping a coin) to one of two groups:

Standard 2D specimen mammography (current standard practice), or

3D digital breast tomosynthesis performed in theatre.

In both groups, the operating surgeon will review the images during surgery and decide whether additional tissue needs to be removed. The final margin status will be determined by routine laboratory analysis after surgery.

The main goal of this study is to compare the rate of positive margins between the two imaging methods. Other outcomes include the need for additional surgery, operating time, and overall workflow efficiency.

The results of this study may help determine whether intraoperative 3D imaging improves surgical outcomes and reduces the need for re-excision in patients undergoing breast-conserving surgery.

Detailed Description

(Technical, structured, avoids repeating registry fields; within 32,000 characters)

Background and Rationale

Breast-conserving surgery (BCS) is a standard surgical treatment for early-stage invasive breast cancer and ductal carcinoma in situ (DCIS). Achieving clear surgical margins is essential to minimise local recurrence risk and reduce the need for re-excision. Despite current intraoperative assessment techniques, reported positive margin rates range from 15-20%, and a substantial proportion of patients require additional surgery.

Intraoperative specimen imaging is used to guide margin assessment. Standard practice involves 2D specimen mammography performed in the radiology department. Limitations of this approach include:

Specimen transport outside the operating theatre Potential workflow delays Limited three-dimensional assessment of tumour-margin relationships Difficulty interpreting complex lesions or microcalcifications Digital breast tomosynthesis (DBT) provides three-dimensional imaging through multiple reconstructed slices. The Mozart 3D Specimen Radiography System enables intraoperative DBT imaging directly within the operating theatre. This may improve visualisation of margins and allow more accurate real-time surgical decision-making.

Prospective observational data suggest improved diagnostic accuracy with intraoperative DBT compared to standard specimen mammography. However, high-quality randomised controlled trial data are limited.

Study Design

The MOZART study is a prospective, single-centre, open-label, parallel-group randomised controlled trial conducted at Beaumont Hospital.

Eligible patients undergoing breast-conserving surgery will be randomised in a 1:1 ratio to:

Standard intraoperative 2D specimen mammography (control group), or

Intraoperative 3D digital breast tomosynthesis using the Mozart system (intervention group).

Randomisation will be computer-generated. Surgeons and participants will not be blinded due to the nature of the intervention. Histopathologists assessing final margin status and data analysts will be blinded to group allocation.

Intervention Procedures Control Group

Specimen imaging will be performed in the radiology department using standard 2D mammography. The operating surgeon will review images and determine whether additional excision is required.

Intervention Group

Specimen imaging will be performed in theatre using the Mozart 3D digital breast tomosynthesis system. The surgeon will assess reconstructed tomosynthesis images in real time and determine whether additional excision is required.

In both groups, standard surgical technique and postoperative management will not be altered.

Outcomes

The primary outcome is the rate of positive surgical margins on final histopathological assessment.

Positive margins are defined according to contemporary national and international guidance as:

Invasive carcinoma at or within 1 mm of the inked margin; or DCIS within 2 mm of the margin.

Secondary outcomes include:

Re-excision rate Operative time metrics Time from specimen removal to imaging review Theatre workflow efficiency Cost-effectiveness analysis

Conditions
Breast Cancer
Being tested
Standard 2D Specimen Mammography, Mozart 3D Specimen Radiography System
Keywords
Breast Cancer, MOZART
Medical subject headings
Breast Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Standard 2D Specimen MammographyProcedure or surgery

    Two-dimensional specimen mammography performed intraoperatively in the radiology department to assess surgical margins following breast-conserving surgery. Images are reviewed by the operating surgeon to guide additional excision if indicated.

  • Mozart 3D Specimen Radiography SystemDevice

    Intraoperative digital breast tomosynthesis imaging performed in theatre using the Mozart 3D Specimen Radiography System (Kubtec). The system generates reconstructed 3D images of the excised specimen to allow real-time assessment of surgical margins by the operating surgeon.

Study groups in NCT07426809
Study groupRoleWhat they receive
Standard 2D Speciman Mammography (Control)Active comparatorParticipants undergo intraoperative specimen imaging using standard two-dimensional (2D) specimen mammography performed in the radiology department following tumour excision. The operating surgeon reviews the images intraoperatively to assess margin adequacy and determines whether additional excision is required prior to wound closure. All other aspects of surgical care follow standard institutional practice.
Receives: Procedure: Standard 2D Specimen Mammography
3D Digital Breast Tomosynthesis (Mozart System Intervention)ExperimentalParticipants undergo intraoperative specimen imaging using three-dimensional (3D) digital breast tomosynthesis with the Mozart 3D Specimen Radiography System, performed directly in the operating theatre. The operating surgeon reviews reconstructed tomosynthesis images in real time to assess margin adequacy and determine whether additional excision is required prior to wound closure. All other aspects of surgical care remain unchanged.
Receives: Device: Mozart 3D Specimen Radiography System

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Rate f positive Surgical Margins

    Proportion of participants with positive margins on final histopathological assessment following breast-conserving surgery.

    A positive margin is defined as:

    Invasive carcinoma at or within 1 mm of the inked surgical margin, or Ductal carcinoma in situ (DCIS) within 2 mm of the inked margin.

    Margin status will be determined by blinded histopathological evaluation of the surgical specimen.

    Measured: Within 4 weeks after index surgery (upon availability of final histopathology report)

Secondary outcomes (5)
  1. Re-Excision Rate

    Proportion of participants requiring return to theatre for re-excision surgery due to positive margins identified on final histopathology.

    Measured: Within 3 months after index surgery

  2. Time From Specimen Removal to Imaging Review

    Time (in minutes) from surgical excision of the specimen to completion of intraoperative imaging review by the operating surgeon.

    Measured: Intraoperative (day of surgery)

  3. Time From Specimen Removal to Skin Closure

    Time (in minutes) from surgical excision of the specimen to final skin closure.

    Measured: Intraoperative (day of surgery)

  4. Total Operative Time

    Total duration of surgery measured in minutes from incision to skin closure.

    Measured: Intraoperative (day of surgery)

  5. Cost-Effectiveness Analysis

    Comparative evaluation of theatre time costs, radiology utilisation, and re-operation rates between intervention and control groups. Incremental cost-effectiveness ratio will be calculated based on cost per margin-negative surgery achieved.

    Measured: At study completion (after all participants have completed follow-up)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted23 Feb 2026
  2. Study start18 Dec 2025
  3. Primary completion31 Dec 2027 (estimated)
  4. Study completion31 Dec 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
Participants undergoing breast-conserving surgery will be randomised in a 1:1 ratio to intraoperative margin assessment using either standard 2D specimen mammography (control group) or intraoperative 3D digital breast tomosynthesis using the Mozart system (intervention group). The assigned imaging modality will guide intraoperative decision-making regarding additional excision. Final histopathological assessment will be performed for all participants and analysed according to allocated group.
Masking
None (open label)
Enrolment
314 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07426809
Sponsor's protocol ID
25-61
Acronym
MOZART
Status last verified
Feb 2026
First submitted
16 Feb 2026
Last updated
3 Apr 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

A study testing Standard 2D Specimen Mammography and Mozart 3D Specimen Radiography System in people with Breast Cancer, run by Royal College of Surgeons, Ireland at 1 site in Ireland.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 3 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Ireland. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Prof Arnold Hill, MB, BCh, BAO, MCh, FRCSI (018093000, adkhill@rcsi.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Rate f positive Surgical Margins (time frame: Within 4 weeks after index surgery (upon availability of final histopathology report)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Apr 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in